Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
COVID-19 infection has spread worldwide causing several deaths in few months Convalescent Plasma from COVID 19 donors has shown huge activity in small series from Chinese patients and currently many centers from USA and the European Union are assessing its use looking to avoid mortality and prolonged hospitalizations COVID-19-related
Description: in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma
Measure: in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma Time: 1 yearDescription: safety of convalescent plasma from COVID 19 donors (CTCAE V5.0)
Measure: safety of the use of convalescent plasma drom COVID 19 donors Time: 1 yearDescription: any cause of mortality during these periods
Measure: Mortality at 30 days, 90 days, 6 months and 1 year Time: 1 yearDescription: based on results from this trial comparing with official information
Measure: in-hospital Mortality COVID-19 related compared with non-treated population according to Chilean official reports Time: through study completion, an average of 1 yearDescription: number of days of hospitalization in high complexity facilities after convalescent plasma use
Measure: Number of days of hospitalization in high complexity facilities after convalescent plasma use Time: 1 yearDescription: number of days of hospitalization in intensive care unit after convalescent plasma use
Measure: Number of days of hospitalization in intensive care unit after convalescent plasma use Time: 1 yearDescription: number of days of mechanical ventilatory support in patients after convalescent plasma use
Measure: Number of days of mechanical ventilatory support in patients after convalescent plasma use Time: 1 yearDescription: total number of days of mechanical ventilatory support
Measure: Total number of days of mechanical ventilatory support Time: 1 yearDescription: total number of hospitalization days in patients treated with convalescent plasma
Measure: Total number of hospitalization days in patients treated with convalescent plasma Time: 1 yearDescription: total number of hospitalization days in patients after treatment with convalescent plasma
Measure: Number of hospitalization days in patients after treatment with convalescent plasma Time: 1 yearDescription: Viral load measuring
Measure: Viral load measuring Time: 14 daysDescription: COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies
Measure: Immunological response in treated patients (COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies) Time: day 1 of hospitalizationDescription: negativization of COVID 19 load since convalescent plasma use
Measure: Negativization of COVID 19 load since convalescent plasma use Time: 14 daysDescription: negativization of COVID 19 load since hospitalization
Measure: Negativization of COVID 19 load since hospitalization Time: 14 daysDescription: negativization of COVID 19 load since first reported symptoms COVID-19 related
Measure: Negativization of COVID 19 load since first reported symptoms COVID-19 related Time: 14 daysDescription: Interferon Gamma measurement from donor
Measure: Donor Interferon Gamma profile characterization Time: 1 dayDescription: Granulocyte Macrophage Colony Stimulating Factor measurement from donor
Measure: Donor Granulocyte Macrophage Colony Stimulating Factor characterization Time: 1 dayDescription: Tumor Necrosis Factor Alfa measurement from donor
Measure: Donor Tumor Necrosis Factor Alfa characterization Time: 1 dayDescription: Interleukin -1 beta measurement from donor
Measure: Donor Interleukin -1 beta characterization Time: 1 dayDescription: Interleukin -2 measurement from donor
Measure: Donor Interleukin-2 characterization Time: 1 dayDescription: Interleukin -4 measurement from donor
Measure: Donor Interleukin-4 characterization Time: 1 dayDescription: Interleukin -6 measurement from donor
Measure: Donor Interleukin-6 characterization Time: 1 dayDescription: Interleukin -8 measurement from donor
Measure: Donor Interleukin-8 characterization Time: 1 dayDescription: Interleukin -10 measurement from donor
Measure: Donor Interleukin-10 characterization Time: 1 dayDescription: Interferon Gamma measurement from receptor
Measure: Receptor Interferon Gamma profile characterization Time: 1 dayDescription: Granulocyte Macrophage Colony Stimulating Factor measurement from receptor
Measure: Receptor Granulocyte Macrophage Colony Stimulating Factor characterization Time: 1 dayDescription: Tumor Necrosis Factor Alfa measurement from receptor
Measure: receptor Tumor Necrosis Factor Alfa characterization Time: 1 dayDescription: Interleukin -1 beta measurement from receptor
Measure: receptor Interleukin -1 beta characterization Time: 1 dayDescription: Interleukin -2 measurement from receptor
Measure: Receptor Interleukin-2 characterization Time: 1 dayDescription: Interleukin -4 measurement from receptor
Measure: Receptor Interleukin-4 characterization Time: 1 dayDescription: Interleukin -6 measurement from receptor
Measure: Receptor Interleukin-6 characterization Time: 1 dayDescription: Interleukin -8 measurement from receptor
Measure: Receptor Interleukin-8 characterization Time: 1 dayDescription: Interleukin -10 measurement from receptor
Measure: Receptor Interleukin-10 characterization Time: 1 dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports